Pancreatic ductal adenocarcinoma (PDAC) is the most common form of human pancreatic cancer, representing more than 95% of all cases. Despite recent advances in surgical techniques and adjuvant therapy, survival has changed little in the last 20 years, with a 5-year survival rate hovering around 5%. Moreover, PDAC incidence has been increasing gradually to over 45,000 new cases in 2013 in the United States alone, where PDAC has been predicted to rapidly become the second most prevalent cancer killer 1 . Although some patients benefit from earlier diagnosis due to emerging imaging technologies (enabling the surgical removal of their tumors), even the most advanced chemotherapeutic regimens and virtually all targeted therapies have remained largely ineffective thus far (reviewed in refs. 2-5).
Recent next-generation sequencing efforts have revealed frequent alterations in genes regulating chromatin remodeling and modification in human tumors 9, 18 , which has led to the idea that the proteins encoded by these genes may be used as therapeutic targets in cancer, including in PDAC (reviewed in refs. 19, 20) . Here we investigate the effect of targeting in PDAC one such family of chromatin regulators, the BET (bromodomain and extra-terminal) family of proteins, which recognize acetylated lysines on histones through their bromodomains (BRD) and control the transcription of oncogenic drivers such as MYC [21] [22] [23] .
RESULTS

BET inhibition suppresses pancreatic tumorigenesis
First we examined the expression of BET family proteins in PDAC. We detected expression of BRD2, BRD3, and BRD4 in preneoplastic lesions and frank tumors in the Ptf1a +/Cre ;Kras +/LSL-G12D mouse model of endogenous PDAC (hereafter referred to as Kras) 12 , in human tumors and in human cell lines (Fig. 1a,b and Supplementary  Fig. 1a,b) . On the basis of these observations, we examined the effects of treating primary mouse pancreatic acinar explants in culture with a small-molecule inhibitor of BET proteins ((+)-JQ-1, hereafter JQ1; ref. 21) . JQ1 treatment blocked acinar-to-ductal metaplasia (ADM), a key step in PDAC initiation 24 observed in response to constant EGF stimulation, which mimics Ras activation (Fig. 1c) . This reprogramming block correlated with decreased c-MYC (hereafter MYC) levels in mouse acinar explants and the pancreas of Kras mice in vivo ( Supplementary Fig. 2a,b) . JQ1 treatment blocked pancreatic cell proliferation and the development of pancreatic intraepithelial neoplastic lesions (PanINs) in a mouse model of PDAC co-triggered by oncogenic K-Ras and caerulein-induced inflammation 25 (Fig. 1d,e and Supplementary Fig. 2a-c) . Immunoblot analysis showed decreased activation of the pro-survival kinase AKT in pancreata from JQ1-treated mice; we also observed downregulation of the activity of inflammatory regulators such as STAT3 and IL6 in pancreata extracts upon JQ1 treatment, correlating with tumor inhibition (Fig. 1f and Supplementary Fig. 2b,c) . These data suggest that JQ1 treatment may have chemopreventive effects in PDAC.
Treatment of human PDAC cell lines with JQ1 also led to lower MYC levels, induction of cell death, and decreased tumorigenic features in culture (Supplementary Fig. 1c-e ; see also ref. 26) . To further investigate the effects of JQ1 treatment on tumor maintenance in vivo, we used a highly aggressive mouse model of PDAC (Ptf1a +/Cre ;Kras +/LSL-G12D ;Trp53 loxP/loxP mice, hereafter referred to as Kras;p53), in which tumors develop within the first 6 weeks of life 11 . Short-term treatment (5 d) with JQ1 after tumors had formed resulted in reduced MYC expression and proliferation and increased apoptosis in this model ( Supplementary Fig. 2d-g ). This led us to investigate the long-term consequences of JQ1 treatment in established PDAC, both as a single agent and in combination with standardof-care chemotherapy (gemcitabine), in a preclinical therapy trial setting 7, 27, 28 . Kras;p53 mutant mice were screened weekly for cancer development by MRI 29 and were enrolled in the study upon development of a tumor volume of approximately 200-400 mm 3 ( Fig. 1g and Supplementary Fig. 3 ). As reported before in various mouse models [29] [30] [31] , gemcitabine monotherapy had no significant effect on tumor composition, tumor volume or mouse survival in this context ( Fig. 1h-j) , similar to what is seen in humans with PDAC. In contrast, JQ1 alone or in combination with gemcitabine led to a significant reduction in tumor volume, an increase in apoptosis and a decrease in proliferation, as well as decreased activity in pro-survival and pro-proliferative pathways (Supplementary Fig. 4) . Inflammatory signals such as STAT3 and IL6 (Fig. 1j) and expression of the tumor-associated stroma marker smooth muscle actin and collagen ( Supplementary Fig. 4 ) were also reduced upon JQ1 treatment. Notably, JQ1 treatment had only a modest effect on survival on its own and did not significantly synergize with chemotherapy under these conditions (Fig. 1h) . Nevertheless, these experiments and recent reports 32, 33 support an acute therapeutic effect of JQ1 treatment in established PDAC tumors in vivo.
BET inhibition blocks MYC and inflammation
To determine how JQ1 treatment blocks PDAC growth, we performed gene set enrichment analysis (GSEA) on gene expression profiles from JQ1-treated and control Kras;p53 mouse primary PDAC cells. This analysis identified a substantial downregulation of MYC targets in JQ1 treated cells (Fig. 2a) . The MYC family of oncogenes has been implicated in the pathogenesis of most types of human tumors, including PDAC 34 , and we confirmed amplification and increased expression of MYC in human and mouse PDAC ( Supplementary Fig. 5a-d ). To investigate a role for MYC in PDAC development, we crossed Kras mice to Myc conditional mutant mice. Unlike Kras mice, which showed the expected formation of preneoplastic lesions, mice with concomitant oncogenic Kras activation and Myc deletion at the time of cancer initiation showed attenuated development of preneoplastic lesions of both low and higher grades ( Fig. 2b and Supplementary Fig. 5e,f) . These data indicate that the inhibitory effects of JQ1 treatment on PDAC cells may in part be mediated by decreased MYC levels; however, BRD family proteins may also control the activity of other drivers of PDAC development.
Inflammatory mediators including STAT3 and IL6 drive pancreatic carcinogenesis [35] [36] [37] [38] . Although MYC is known to promote tumorigenesis by controlling the tumor microenvironment 39 , we did not observe significant changes in pSTAT3 levels, inflammatory molecules or tumor stromal response in the absence of MYC ( Supplementary Fig. 5e and data not shown). In contrast, we observed a marked reduction in IL6 and phospho-STAT3 (pSTAT3) levels in Kras;p53 mutant mice treated with JQ1 ( Fig. 1j and Supplementary Fig. 4a ). Furthermore, GSEA of JQ1-treated and control tumors revealed that signatures for growth factors, cytokines and immune-related processes were significantly decreased in JQ1-treated mice ( Fig. 2c and Supplementary  Fig. 5g-i) . On the basis of these observations, we analyzed the serum of wild-type, control and JQ1-treated mice and found lower levels of inflammatory cytokines, including IL1a and IL6, in the serum of JQ1-treated animals (Fig. 2d) . IL1a and IL6 both promote pancreatic tumorigenesis 35, 36, 40, 41 . Reduced levels of IL1A and IL6 mRNA were also noted in xenografts derived from humans with PDAC (patientderived xenografts, PDXs) treated with JQ1 (Fig. 2e) . In addition, we observed a correlation between the expression levels of BET family members, MYC and a set of cytokines in human PDAC, further indicating that JQ1 treatment broadly affects inflammatory molecules (Supplementary Fig. 5j ). Like JQ1 treatment, shRNA-mediated knockdown of BRD4 led to the downregulation of IL6 and pSTAT3 in human CFPac1 PDAC cells in culture, supporting a cell-intrinsic role for BET proteins in the regulation of the expression of inflammatory mediators in PDAC cells (Fig. 2f) . Furthermore, chromatin immunoprecipitation assays in CFPac1 cells showed direct BRD4 association to the IL6 promoter, which was disrupted by JQ1 pretreatment (Fig. 2g,h) . Finally, the protective effect of JQ1 treatment on tumor development could be reversed by exogenous injections of IL6, which npg a r t i c l e s nature medicine VOLUME 21 | NUMBER 10 | OCTOBER 2015 1 1 6 5 led to reactivation of STAT3 phosphorylation and accelerated tumorigenesis (Fig. 2i,j and Supplementary Fig. 6 ). Collectively, these observations indicate that, in addition to MYC, inflammatory signals represent a second oncogenic driver that is downstream of BET family proteins in pancreatic tumorigenesis.
Synergistic effects of JQ1 and the HDAC inhibitor SAHA JQ1-treated mice eventually succumbed to PDAC (Fig. 1h) . This led us to investigate additional agents that could be combined with JQ1 to more durably suppress PDAC. We selected eight drugs that target key Ras-dependent oncogenic or CDKN2A-or TP53-dependent pathways or epigenetic regulators, and established a cell culture assay to screen for effective combination therapies. Inhibition of histone deacetylases (HDACs) with the small molecule SAHA (vorinostat) had a synergistic effect with BET protein inhibition in human CFPac1 cells, whereas other drug combinations were less effective ( Fig. 3a and Supplementary Fig. 7 ). Co-treatment with JQ1 and SAHA led to a strong reduction in cell viability (Fig. 3b) , which correlated with marked induction of apoptosis as measured by annexin V staining, caspase 3 cleavage and reduction of expression of the anti-apoptotic proteins MCL1 and BCL-XL in several PDAC cell lines; in addition, JQ1 and SAHA treatment blocked the ability of human and mouse PDAC cells to form colonies at low density, a measure of decreased tumorigenic potential (Fig. 3b-e and Supplementary Fig. 8 ). JQ1 and SAHA also synergized to suppress the formation of MUC5AC-positive preneoplastic lesions in Kras mutant mice (Fig. 3f-h and Supplementary Fig. 9 ). Based on these experiments on cancer initiation in vivo and tumor maintenance in vitro, we next evaluated the effect of combined JQ1+SAHA treatment on established PDAC in vivo. Kras;p53 mutant mice treated with JQ1+SAHA after development of a tumor volume of 200-400 mm 3 (Supplementary Fig. 3 ) showed a greatly reduced tumor volume, more so than Kras;p53 mutant mice treated with JQ1 alone, and had a significant improvement in overall survival Supplementary Fig. 3 ) of mice in the treatment groups: control, n = 9; Gem, n = 5; JQ1, n = 6; Gem + JQ1, n = 6. *P < 0.05; ***P < 0.001; n.s., not significant (two-tailed unpaired Student's t-test). Data are represented as mean ± s.e.m. (j) Immunoblot analysis of MYC, phospho-STAT3 (pSTAT3), phospho-AKT (pAKT) and IL6 levels in tumor biopsies collected from control and JQ1-treated Kras;p53 mutant mice (multiple independent mouse tumors were obtained and analyzed, two independent and representative samples are shown). npg a r t i c l e s 1 1 6 6 VOLUME 21 | NUMBER 10 | OCTOBER 2015 nature medicine (Fig. 4a-d) . Of note, 4 of 10 mice treated in the combination arm had to be euthanized because of neurological symptoms due to Cre expression and tumor development in the brain 42 (data not shown); this is usually not an issue in this mouse model because these mice normally die much faster from PDAC. Five of the remaining mice treated with the combination therapy developed bile drainage problems and were morbid due to jaundice rather than high tumor burden; one mouse died of unknown cause. Importantly, mice treated with JQ1+SAHA showed no evidence of tumor relapse, a sign of inherent or acquired resistance, such as is typically seen with other therapies, nor did they develop metastasis (data not shown). Residual small tumor clusters had a moderately differentiated histology, with some poorly or undifferentiated areas with strongly depleted stroma. The combination therapy led to a significant cell cycle inhibition (P < 0.05) and a significant increase in apoptotic cell death (P < 0.001) compared to JQ1 treatment alone (Supplementary Fig. 10 ).
A similar therapeutic effect was observed in a second highly aggressive mouse model of PDAC (Ptf1a +/Cre ;Kras +/LSL-G12D p16/p19 loxP/loxP mutant mice, hereafter Kras;p16/ 19) , in which tumors develop with a latency of 8 weeks 43 ( Supplementary Fig. 11a-d) . Also, the combination therapy significantly inhibited the growth of two independent PDAC PDXs; this growth suppression was accompanied by reduced expression of MYC and pSTAT3 and reduced stromal response (Fig. 4e-g and Supplementary Fig. 11e-i) .
Typically, increased cancer tumor burden is accompanied by the development of cachexia, but this weight loss was completely prevented by JQ1+SAHA treatment (Supplementary Fig. 12a,b) . In addition, the histopathology and blood markers of the treated mice revealed no overt systemic toxicity due to the combination therapy ( Supplementary Fig. 12c-h) . Thus, the combined inhibition of BET family proteins and HDACs results in a potent and sustained antitumoral response. To investigate whether the JQ1+SAHA combination therapy could be effective in other tumor types, we performed another set of experiments in lung cancer cells. As in PDAC, MYC and BET family proteins, including BRD4, were expressed in human lung adenocarcinoma (LAC) (Supplementary Fig. 13a-c) . In a wellestablished mouse model of LAC based on activation of Kras G12D and loss of p53 (ref. 44) , treatment with JQ1 and SAHA 70 d after cancer initiation, when mice have developed tumors, significantly increased the survival of the mutant mice ( Fig. 5a-c) , associated with lower MYC levels, induction of cell death, and inhibition of proliferation ( Supplementary Fig. 13c-g ). Similarly, a lung cancer PDX showed significant growth inhibition upon JQ1 and SAHA treatment (Fig. 5d,e) . Thus, the combination therapy seems to be effective against several types of transformed cells and tumor entities.
In vivo gene-editing identifies the role of p57
To investigate the molecular basis for the strong induction of apoptotic cell death in tumors treated with JQ1 and SAHA, we analyzed gene expression profiles of primary cells from Kras;p53 mutant mice and biopsy tissue from human PDX treated with JQ1 or SAHA alone or in combination. GSEA of microarray data showed decreased expression of HDAC targets in JQ1+SAHA-treated primary cells from Kras;p53 mutant mice and in human PDX, as well as a general decrease in transcription, as would be expected ( Supplementary  Fig. 14a ). Signatures for increased apoptosis and decreased mitosis were also highly enriched in JQ1+SAHA-treated human and mouse cells (Supplementary Fig. 14a) . p57 (officially known as Cdkn1c) was the most synergistically de-repressed gene seen in an analysis of microarray data from JQ1+SAHA-treated mouse PDAC cells (Supplementary Fig. 14b ). Defining synergy as an effect in excess over an additive effect of the two drugs, p57 mRNA levels were increased on average 3.28-fold over additivity. Interestingly, p57 transcription is repressed by MYC 45 . p57 transcription is also often silenced in PDAC by epigenetic mechanisms, and its expression can be restored by HDAC inhibition 46 . This increase in p57 mRNA expression was validated at the protein level (Fig. 6a,b) . Depletion of p57 using shRNA led to reduced levels of the apoptotic marker PARP in PDAC cells treated with JQ1+SAHA in culture (Fig. 6c) , supporting a previously suggested role for p57 in promoting apoptosis 47, 48 . We found increased acetylation of the p57 promoter by chromatin immunoprecipitation upon JQ1+SAHA treatment, correlating promoter acetylation with p57 expression (Fig. 6d) .
These experiments in primary cells from Kras;p53 mutant mice and in human PDX led us to investigate whether de-repression of p57 was in part responsible for the induction of cell death observed following inhibition of BET proteins and HDACs. To this end, we developed an approach of lentiviral injections in the pancreas of adult mice based on reagents recently developed to manipulate gene expression using the CRISPR-Cas9 system in the lung 49 . We cloned a single-guide RNA (sgRNA) targeting the mouse p57 gene (sgp57) into the pSECC lentiviral backbone and examined the consequences of deleting p57 in mouse PDAC tumors treated with JQ1+SAHA (Fig. 6e,f) . Cohorts of Kras;p53 mutant mice were infected with pSECC-sgp57 or pSECC-sgControl (with a scrambled sgRNA) lentiviral vectors by direct injection into the mouse pancreas (Supplementary Fig. 15a ). Although adult mice are refractory to Kras-induced pancreas tumorigenesis 50, 51 , this block was overcome by inducing moderate pancreatitis with caerulein 29 (Fig. 6f) . Successful recombination of the alleles flanked by loxP sites by the Cre recombinase was confirmed by the activation of a reporter allele ( Fig. 6g and Supplementary Fig. 15a ). Induction of Cas9-mediated mutations in the p57 gene was verified using a Surveyor assay (Fig. 6h) . Using this protocol, we observed that 3 of 8 mice developed tumors that lacked p57 expression, with 4 additional mice showing partial loss (at least 70%), upon JQ1+SAHA treatment. All treated sgRNA-control animals expressed p57 under the same conditions ( Fig. 6i and Supplementary Fig. 15b,c) . Notably, tumors with successful deletion of p57 showed a significant (P < 0.01) reduction in apoptosis when treated with JQ1+SAHA
as compared to tumors treated with the combination therapy but infected with a control lentiviral vector (Fig. 6i) , partially reversing the therapeutic effects of the combination therapy. Thus, p57 may be one of the key mediators of the anticancer action of JQ1 and SAHA in PDAC cells.
DISCUSSION
In this study we examined the possible use of small-molecule inhibitors of chromatin regulators in adenocarcinoma of the pancreas and the lung and found a potent synergistic tumor-suppressive effect between a specific inhibitor of the BET family proteins (JQ1, known npg as TEN-010 in clinical trials) and HDAC proteins (SAHA, also known as vorinostat, an FDA-approved drug). Although the mode of action of the two drugs is certainly multifaceted and certainly involves broad signaling and transcriptional changes in both tumor cells and the tumor stroma, we identified transcriptional induction of p57 as a key mediator of cell death upon JQ1+SAHA treatment in PDAC cells. We also noted faster migration for a pool of p57 protein upon treatment with JQ1+SAHA (see, for example, immunoblots in Fig. 6a,b) , an effect which might be related to decreased phosphorylation of p57 by AKT, an event previously associated with higher p57 turnover rates 52 ; this could provide an additional mechanism of p57 activation in this context. On the basis of these observations, we propose that MYC downregulation, reduced inflammation, and p57 induction are some of the processes affected by JQ1 and SAHA in tumors (Fig. 6j) , and we suggest that p57 status may be used as a possible biomarker for how tumors respond to the combined treatment.
Recently, a combination of a HDAC inhibitor and a demethylase inhibitor was found to synergistically inhibit a subtype of glioma 53 . Similarly, loss of the chromatin remodeler EZH2 has been shown to amplify Ras-driven transcription in glioma and melanoma and enhance the sensitivity of tumor cells to BRD4-based strategies 54 . Thus, combinations of small-molecule inhibitors targeting chromatin regulators may have limited toxicity and strong inhibitory effects in many cancer types. Future studies will investigate whether the marked response to JQ1 and SAHA is specific to PDAC and LAC, two cancers with important stromal and inflammatory components. In particular, the inhibitory effects of JQ1 in a mouse model of Ras-driven lung adenocarcinoma are dependent on the tumor genotype, with loss of the Lkb1 tumor suppressor largely abolishing the anticancer effects of this drug 55 . Although we have performed our experiments with tumors bearing the most frequent genetic alterations in PDAC and LAC, it will be important in the future to investigate the effects of combined BET and HDAC inhibitors on subgroups of tumors with multiple genotypes. Nevertheless, our experiments identify a striking vulnerability to epigenetic-based targeting approaches in pancreatic and lung cancers, two tumor types that are largely resistant to current therapeutic approaches, and will hopefully facilitate the rapid clinical evaluation of this new strategy. 
Kras +/LSL-G12D ;p53 loxP/loxP
Cre-Cas9-sgControl Cre-Cas9-sgp57 12, 43, [56] [57] [58] [59] . Mice were in a mixed C57BL/6;129/Sv background, and we systematically used littermates as controls in all the experiments (sex ratio per cohort balanced). All animals were numbered and experiments were conducted in a blinded fashion. After data collection, genotypes were revealed and animals assigned to groups for analysis. For treatment experiments mice were randomized. None of the mice with the appropriate genotype were excluded from this study. Histopathological analysis was conducted on de-identified slides by two pathologists (I.E. and B.S.). Animal experiments and care were in accordance with the guidelines of institutional authorities and approved by local authorities (see Ethics statement).
Pancreatic cancer mouse models. Pancreatitis-induced tumorigenesis. Acute pancreatitis was induced at 6 to 8 weeks of age in Ptf1a +/Cre ;Kras +/LSL-G12D (Kras) mice by administration of 8 hourly intraperitoneal (IP) injections of caerulein (100 µg/kg body weight) (Sigma-Aldrich) over 2 consecutive days as described previously 25, 60 . Mice were treated as indicated with JQ1 (25 mg/kg twice daily, IP) and/or SAHA (25 mg/kg, once daily, Selleckchem) or vehicle 10% (2-hydroxypropyl)-β-cyclodextrin (Sigma-Aldrich). The twice-daily injection regiment for JQ1 is based on in vivo drug stability data 61 . IL6 injections were performed intravenously (i.v.) (mouse recombinant IL6, 1 µg per mouse). Pancreatic lesions were analyzed 7 d after the last injection. In parallel animals were analyzed at day 0 to confirm the caerulein-induced damage. None of the treatments affected the initial pancreatic injury (data not shown).
Spontaneous model of pancreatic intraepithelial neoplasia (PanIN) development.
PanIN progression was analyzed in Ptf1a +/Cre ;Kras +/LSL-G12D (Kras) and Ptf1a +/Cre ;Kras +/LSL-G12D ; Myc loxP/loxP (Kras;Myc) mice aged 6 months. Quantification of low-(PanIN1a and 1b) and high-grade (PanIN2 and 3) lesions was performed by a pathologist (B.S.). Histopathological analysis was conducted on de-identified slides based on the classification consensus 62 . Five images (×100) were taken in standardized positions (so as to cover the whole section) for each slide. PanINs were counted from 8 independent animals for each group. Error bars represent s.e.m.
To calculate the relative normal acini area, Kras and Kras;Myc tumor sections were stained for amylase. Positive regions on six random, nonoverlapping, ×100 images were collected from 3 mice per genotype. For each image positive amylase area was normalized to total pancreas tissue area using ImageJ software. Error bars represent s.e.m.
Model of aggressive PDAC-long-term treatment.
For survival studies, we used Ptf1a +/Cre ;Kras +/LSL-G12D ;Trp53 loxP/loxP (Kras;p53) mice, which develop aggressive, quickly fatal disease. Mice were followed for signs of disease progression. At the end of the experiment, tumors were processed for biochemical, histological and immunohistochemical analysis.
Mice were treated as indicated with JQ1 (25 mg/kg twice daily, IP) and/or SAHA (25 mg/kg, once daily, Sigma-Aldrich) or vehicle 10% (2-hydroxypropyl)-β-cyclodextrin (Sigma-Aldrich). Gemcitabine (Sigma) was dissolved in saline and dosed at 100 mg/kg of gemcitabine on a Q3Dx4 schedule (every third day for 4 cycles) as previously described 30, 63 .
Model of aggressive PDAC-acute treatment. To study the short-term effects of JQ1 treatment on Kras;p53 mutant tumors, 35d old animals with fully developed PDAC were treated with JQ1 (25 mg/kg twice daily, IP) over 5 d.
CRISPR-Cas9-mediated direct genome editing in the mouse pancreas.
Plasmid and lentivirus preparation. The U6-sgRNA-EFS-Cas9-2A-Cre (pSECC) lentiviral vector was described previously 49 . For sgRNA cloning, the pSECC vector was digested with BsmBI and ligated with annealed oligos with complementary BsmBI fragments. Specific sgRNAs were designed using CRISPR Design 64, 65 to avoid potential off-target sites. A Cdkn1c specific guide RNA (PAM sequence underlined) pre-validated in vitro was used: GCGC TGCTACGCGCTATCACTGG. Lentivirus was produced and titered as described previously 66 . Briefly, the pSECC vector was co-transfected with packaging vectors into 293T cells using polyethylenimine (PEI) transfection. The supernatant was collected at 48, 72 and 96 h. Concentrated virus was recovered by ultracentrifugation at 25,000 r.p.m. for 120 min and re-suspended in 25 µl PBS with 1% (vol/vol) Matrigel (BD Matrigel Growth Factor Reduced, BD Biosciences).
Lentiviral injections to the pancreas. pSECC allows expression of target sgRNA and the Cas9 nuclease with the Cre recombinase. This results in simultaneous genome editing and Cre-mediated activation of Kras G12D and ablation of Trp53 in infected mouse pancreata. This model enables rapid, flexible, and scalable investigation of gene function in vivo. Cohorts of Kras +/LSL-G12D ;Trp53 loxP/loxP mice were infected with pSECC-sgp57 or pSECC-sgControl lentiviral vectors by direct injection into the pancreas. The recipient mice were anesthetized with isoflurane. Anesthesia depth was assessed based on withdrawal reflex immediately before making an incision and monitored continuously during the surgery. The hair on the ventral surface of the mouse was shaved and the incision site was disinfected with iodophors (Betadine scrub). A disposable surgical drape (precut and sterilized) was placed, and mice were subjected to laparotomy. The incision size was ~1 cm long depending on the size of the individual animal. The splenic part of the pancreas was exposed and the viral solution was slowly injected into the pancreas parenchyma using a 30-gauge needle over 30 s to avoid backward flow. The addition of Matrigel to the injected virus solutions resulted in immediate increased viscosity of the injected fluid and mitigated leakage to prevent transduction outside of the pancreatic tissue (see Supplementary Fig. 15 ). This injection procedure mimics the previously described protocols for xenograft cell implantation 67 . The successful introduction of lentiviral particles into the pancreas parenchyma does not lead to significant side effects, such as pancreatitis, as previously described for intraductal viral administration 68 . Risk of vascular damage can be minimized by passing the needle parallel to any visible vessels, along the length of the pancreas. Finally, the abdominal muscle layer was closed with interrupted suture and the overlying skin was closed using Monocryl sutures (Ethicon).
Pancreatitis induction and treatment. Adult mice normally become refractory to Kras G12D -induced pancreas tumorigenesis, but if these mice are challenged with a mild form of chronic pancreatitis, they develop the full spectrum of PanINs and invasive PDAC 50 . Thus, mice were "primed" with 250 µg/kg caerulein twice daily for 5 consecutive days 29 after lentiviral injection. All successfully transduced animals developed pancreatic tumors. We did not observe sarcoma development in the pancreas, however, in one case we noticed a mesenteric tumor and in few cases neoplastic growth in the peritoneal cavity around the area where the injection was performed.
Analysis of p57 positive areas. Tumor sections were immunostained for p57. For each tumor, the p57-positive area was normalized to the total tumor area using ImageJ software. The distribution of p57 staining status in all infected animals was divided in three groups: negative (<30% of the tumor area stained positive for p57), mixed (30-70% of tumor area stained positive for p57) and positive tumors (70-100% of the tumor area stained positive for p57).
Confirmation of Cas9 targeted loci mutation by T7E1 assay (Surveyor assay). Mutation detection using the T7 (Surveyor) nuclease was performed as previously described 69 . Briefly, PCR products spanning the potential repair/damage sites were amplified and a mixture of 9 µl of PCR products and 1 µl of NEB buffer 2 was melted and re-annealed in a thermal cycler under the following conditions: 95 °C for 10 min, 95 °C to 85 °C at 2 °C/s, 85 °C for 1 min, 85 °C to 25 °C at 0.1 °C/s, 25 °C for 1 min and 4 °C for an indefinite period. Exactly 6 µl of the re-annealed mixture was treated with 0.5 µl of T7 endonuclease I (5 units) by addition of 0.4 µl of NEB buffer 2 and 3.1 µl of ddH2O at 37 °C for 20 min. Analysis by 2% agarose-gel electrophoresis followed. The gel was stained with 1 µg/ml ethidium bromide in Tris-acetate-EDTA buffer for 5 min and then imaged with a gel-imaging system (Bio-Rad).
In vivo imaging and tumor volume measurements. As a model of locally advanced PDAC for imaging-guided tumor response evaluation, we used Kras;p53 mutant mice. MR imaging experiments were initiated at an age of approximately 30 d and were performed weekly. Before imaging, mice were anesthetized by continuous gaseous infusion of 2% isoflurane (Abbott) for at least 10 min using a veterinary anesthesia System (Vetland Medical). During imaging, the npg dose was kept at 2% isoflurane, animal temperature was maintained and continuously monitored and eyes were protected with an eye ointment. Tumor growth kinetics changes were followed with T2 weighted imaging protocol using microscopy surface coil inside a Philips 1.5T or 3.0T clinical scanner. An axial multi-slice T2-weighted (T2w) TSE sequence (resolution 0.3 × 0.3 × 0.7 mm 3 , minimum 30 slices, TE = 90 ms, TR>3 s) was applied for tumor detection. Solid tumor volumes were calculated using in house optimized ImageJ based software that differentiates between solid and cystic parts of the tumor ( Supplementary  Fig. 3a) . By analyzing multiple mice at sequential time points, we found PDAC development occurring at 4-6 weeks in Kras;p53 mutant mice with 100% penetrance. On average, tumors of animals at age 41 d met inclusion criteria of 200-400 mm 3 of tumor mass (Supplementary Fig. 3b ).
Preparation of pancreatic epithelial explants culture. Pancreatic epithelial explants from 4-to 6-week old wild-type mice were established by modification of previously published protocols 60 . In brief, the whole pancreas was harvested and treated twice with 1.2 mg/ml collagenase-VIII (Sigma-Aldrich). Following multiple wash steps with McCoy's medium containing soybean trypsin inhibitor (SBTI, 0.2 mg/ml), digested samples were filtered through a 100 µm filter, resuspended in culture medium (Waymouth's MB 752/1 supplemented with 0.1% BSA, 0.2 mg/ml SBTI; 50 µg/ml bovine pituitary extract, 10 µg/ml Insulin, 5 µg/ml transferrin, 6.7 ng/ml selenium in 30% FCS) and allowed to recover for 1h at 37 °C. Thereafter, cells were pelleted and resuspended in culture medium supplemented with penicillin G (1000 U/ml), streptomycin (100 µg/ml), amphotericin B, 0.1% FCS, and an equal volume of rat tail collagen and immediately plated on plates pre-coated with 2.5 mg/ml of rat tail collagen type I. In stimulation experiments, recombinant human EGF (rhEGF, Invitrogen) was added at final concentration of 25 ng/ml. Cells were treated with JQ1 at a concentration of 250 nM. For quantification, acinar explants were seeded in triplicates. Cell clusters were counted from at least 3 optical fields/well and reported as a percentage of acinar clusters and duct-like spheres. The quantification was performed in two independent experiments; the number of mice is reported in the main text.
Lung adenocarcinoma (LAC) mouse model. Kras +/LSL-G12D ;Trp53 loxP/loxP (Kras;p53) mice were treated with 5 × 10 6 pfu of adenovirus expressing Cre (University of Iowa adenovirus core) by intratracheal infection as previously described 70 .
Patient fresh PDAC biopsies and patient-derived xenograft (PDX) tumors.
Tissue samples were collected from patients following pancreatic resection for PDAC at the Technische Universität München and Ruhr-University Bochum. All patients were informed and written consent was obtained. The tissue collection was performed according to a protocol approved by the Ethics Committee of the Ruhr-University Bochum (permission no. 3534-09 and 3841-10) and the Ethics Committee of the Technische Universität München (Project number: 5510/12). The lung adenocarcinoma (LAC) patient-derived xenograft (Fig. 5) was obtained from the Stanford University medical center following IRB approval. The LAC sample bears a Kras G12V mutation and is wild-type for EGFR and ALK. PDAC samples have Kras G12V mutations and did not express CDKN2A transcripts.
The fresh tumor samples were initially grown directly in the mouse as a tissue fragment. Then tumors were minced using a razor blade and digested in collagenase/dispase digestion buffer (Roche) for 1 h at 37 °C. Cells were passed through 10 µm and 40 µm cell strainers and centrifuged for 1,200 rpm for 8 min. Cells were incubated in RBC lysis buffer for 2 min and then resuspended in 6 ml of media and spun through 0.5 ml of serum layered on the bottom of the tube to remove cellular debris. Cells were depleted of lineage-positive cells using biotin conjugated anti-mouse CD45, CD31 and Ter119 (eBiosciences) and depleted on a MACS LS column (Miltenyi Biotec) using anti-biotin microbeads per the manufacturer's directions. After this procedure, single cells (500,000) were mixed with Matrigel (BD Biosciences) and injected into 6-to 8-week-old female NOD/scid mouse flank. Tumor volume was measured at the times indicated and calculated using the ellipsoid formula (length × width 2 ).
Xenograft tumors (Supplementary Fig. 11e-i ) from early passage human PDACs were grown in female NMRI-nu/nu mice treated with vehicle or JQ1 and SAHA (JQ1 50 mg/kg, SAHA 25 mg/kg once daily) for 21 d.
Serum analysis and cytokine ELISA. Cytokine concentrations in serum were measured using the Mouse Inflammatory Cytokines & Chemokines Multi-Analyte ELISArray Kit (Qiagen) according to the manufacturer's specifications. Data are presented as relative to the WT and treatment controls. Sera were collected from the blood samples of individual mice at the end of the experiment under terminal anesthesia following a protocol for cardiac puncture. Serum samples were separated from blood within 1 h following blood collection by centrifugation at 500g for 10 min. Separated samples were aliquotted and stored at −80 °C for subsequent testing. Media concentration of IL-6 was measured using human-specific ELISA kits (Pierce) according to the manufacturer's protocols.
Aspartate transaminase (AST), alanine transaminase (ALT) and blood urea nitrogen (BUN) levels were measured in serum prepared as indicated above at the Animal Diagnostic Laboratory at Stanford Veterinary Service Center.
Histology and immunohistochemistry.
Tissue specimens were fixed in 4% buffered formalin for 24 h and stored in 70% ethanol until paraffin embedding. 3-µm sections were stained with hematoxylin and eosin (HE), Sirius Red or used for immunohistochemical studies.
Immunohistochemistry was performed on formalin-fixed, paraffin embedded mouse and human tissue sections using a biotin-avidin method as described before 71 Cell culture, reagents and transfections. Authenticated cancer cells (of various genotypes): CFPac1 (Kras G12V ;p53 C242R ), Panc1 (Kras G12D ;p53 R273H ), CaPan1 (Kras G12V ;p53 A159V ;Smad4 S343* ), CaPan2 (Kras G12D ;p53 T125C ), HPFAII (Kras G12D ;p53 T151S ;Cdkn2a R29_A34del ), Colo357 (Kras G12V ;Smad4 mut ), Panc89 (p53 mut ;Cdkn2a mut ), PaTu8902 (Kras G12V ;p53 C176S ), SW1990 (Kras G12D ;p53 P191del ), AsPC1 (Kras G12D ;p53 C135fs*35 :Smad4 R100T ), MiaPaCa2 (Kras G12C ;p53 R248W ), YPAC (Kras G12V ;p53 H179R ;Smad4 R515fs*22 ), BxPC1 (p53 Y220C ), 293T were obtained from the American Type Culture Collection and DanG (Kras G12V ;p53 993+16del.38 ;Smad4 mut ) cells were obtained from CLS Cell Lines Service GmbH and cultured in RPMI Medium supplemented with 10% FCS (Life Technologies), 100 units/ml penicillin/streptomycin and glutamine (Life Technologies). Primary mouse pancreatic cancer lines were obtained from Kras;p53 mouse PDAC. Cells were grown in Dulbecco's modified Eagle's medium (Life Technologies) supplemented with 10% FCS (Life Technologies), 100 units/ml penicillin/streptomycin and glutamine (Life Technologies). All cells were cultured at 37 °C in a humidified incubator with 5% CO 2 . All cell lines were routinely evaluated for mycoplasma contamination. Lentiviral shRNA constructs. shRNA sequences targeting MYC, BRD4 and p57, published previously 72 , were cloned in a pLKO vector carrying a puromycin resistance gene. Lentiviruses were generated in 293T cells using secondgeneration packaging vectors. Target cells were infected and selected using puromycin selection (2 µg/ml puromycin for 1 week, Invitrogen).
Cell assays. Cell viability. Cells were seeded in 96-well plates at 2,000 cells per well (optimal density for growth) in a total volume of 100 µl media containing 2% FBS. Serially diluted compounds in 100 µl media were added to the cells 12 h later. After 72 h incubation, cell viability was assessed by an MTT assay (Roche) according to the manufacturer's instructions.
npg Meta-analysis of public PDAC data sets. We downloaded raw data for 7 publicly available PDAC gene expression studies from the NCBI GEO and EBI ArrayExpress. After re-annotating the probes, each data set was separately normalized using GCRMA. We applied two meta-analysis approaches to the normalized data 77 . Briefly, the first approach combines effect sizes from each data set into a meta-effect size to estimate the amount of change in expression across all data sets. For each gene in each data set, an effect size was computed using Hedges' adjusted g. If multiple probes mapped to a gene, the effect size for each gene was summarized using the fixed effect inverse-variance model. We combined study-specific effect sizes to obtain the pooled effect size and its standard error using the random effects inverse-variance technique. We computed z-statistics as a ratio of the pooled effect size to its standard error for each gene, and compared the result to a standard normal distribution to obtain a nominal P-value. P-values were corrected for multiple hypotheses testing using FDR 78 . We used a second non-parametric meta-analysis that combines P-values from individual experiments to identify genes with a large effect size in all datasets. Briefly, we calculated a t-statistic for each gene in each study. After computing one-tail P-values for each gene, they were corrected for multiple hypotheses using FDR. Next, we used Fisher's sum of logs method, which sums the logarithm of corrected P-values across all data sets for each gene, and compares the sum against a chi-square distribution with 2k degrees of freedom, where k is the number of data sets used in the analysis.
Gene Chip analysis and GSEA. For expression profiling, primary mouse PDAC cells treated with vehicle, JQ1 (1 µM), SAHA (2 µM) or JQ1+SAHA (1 µM/2 µM) for 6 h and JQ1+SAHA-treated and control tissue samples of the patient-derived xenografts ( Supplementary Fig. 11e-i) were used.
Total RNA was isolated using the Qiagen RNeasy Isolation Kit. RNA quality was assessed on an Agilent 2100 Bioanalyser, RNA 6000 Pico Series II Chips (Agilent). A total of 6 µg of labeled RNA was hybridized to mouse (Mouse Genome 430 p.m. 16-Array Plate; Affymetrix) or human (Agilent Human Genome Oligo Microarrays) expression gene chip arrays according to the manufacturer's protocols. The microarray protocols and data reported in this article have been deposited in NCBI's Gene Expression Omnibus (GEO) database, accession numbers GSE 64836 and 64837. GSEA software was provided by the Broad Institute of the Massachusetts Institute of Technology and Harvard University (http://www.broad.mit.edu/gsea/) 79 . For both gene sets, we used the default parameters of the GSEA software package; the genes set permutation was used. In brief, the normalized enrichment score (NES) provides "the degree to which a gene set is overrepresented at the top or bottom of a ranked list of genes. " The false discovery rate q-value (FDR) is "the estimated probability that a gene set with a given NES represents a false positive finding". In general, given the lack of coherence in most expression data sets and the relatively small number of gene sets being analyzed, an FDR cutoff of 25% was considered appropriate.
Gene expression correlation. Heatmaps represent the Pearson correlation between expression of the noted genes in GSE15471 human pancreatic cancer expression data set. Heatmaps were created in R using the "pheatmap" package.
Statistics. Kaplan-Meier survival curves were calculated using the survival time for each mouse from all littermate groups. The log-rank test was used to test for significant differences between the groups. For image quantification and gene expression analysis, statistical significance was assayed by Student's t-test with Prism GraphPad software (two-tailed unpaired and paired t-test depending on the experiment-variance was first systematically examined using an F-test). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns: not significant. Data are represented as mean ± s.e.m.
